Novel structural analogues of piperine as inhibitors of the NorA efflux pump of Staphylococcus aureus

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 6, 2008, Pages 1270-1276

  Kumar, Ashwani ^a   Khan, Inshad Ali ^a   Koul, Surrinder ^a   Koul, Jawahir Lal ^a   Taneja, Subhash Chandra ^a   Ali, Intzar ^a   Ali, Furqan ^a   Sharma, Sandeep ^a   Mirza, Zahid Mehmood ^a   Kumar, Manoj ^a   Sangwan, Pyare Lal ^a   Gupta, Pankaj ^a   Thota, Niranjan ^a   Qazi, Ghulam Nabi ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Ciprofloxacin; Efflux pump inhibitors; Microbial resistance

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; ETHIDIUM BROMIDE; MULTIDRUG RESISTANCE PROTEIN; NORA PROTEIN; PIPERINE; PIPERINE DERIVATIVE; PROTEIN INHIBITOR; QUINOLONE DERIVATIVE; RESERPINE; SK 20; SK 29; SK 56; VERAPAMIL;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; GENE OVEREXPRESSION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; WILD TYPE;

ALKALOIDS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BENZODIOXOLES; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; ETHIDIUM; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MOLECULAR STRUCTURE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION; PIPERIDINES; POLYUNSATURATED ALKAMIDES; STAPHYLOCOCCUS AUREUS;

EID: 44449131356     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn088     Document Type: Article

References (34)

1. Hooper DC. Efflux pumps and nosocomial antibiotic resistance: A primer for hospital epidemiologists. Clin Infect Dis 2005; 40: 1811-7.
2. Webber MA, Piddock LJV. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother 2003; 51: 9-11.
3. Van Bambeke F, Balzi E, Tulkens PM. Antibiotic efflux pumps. Biochem Pharmacol 2000; 60: 457-70.
4. Hsieh PC, Siegel SA, Rogers B et al. Bacteria lacking a multi-drug pump: A sensitive tool for drug discovery. Proc Natl Acad Sci USA 1998; 95: 6602-6.
5. Lomovskaya O, Lee A, Hoshino K et al. Use of genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 199; 43: 1340-6.
6. Kumar A, Schweizer HP. Bacterial resisance to antibiotics: Active efflux and reduced uptake. Adv Drug Deliv Rev 2005; 57: 1486-513.
7. Lawrence LE, Barrett JF. Inhibition of bacterial efflux: Needs, opportunities, and strategies. Curr Antiiinfect Investig Drugs 2000; 2: 145-53.
8. Kaatz GW, Seo SM, Ruble CA. Efflux mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1992; 37 1086-94.
9. Gibbons S, Moser E, Kaatz GW. Catechin gallates inhibit multi-drug resistance (MDR) in Staphylococcus aureus. Planta Med 2004; 70 1240-2.
10. Kaatz GW, Moudgal VV, Seo SM et al. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 719-26.
11. Kaatz GW, Moudgal VV, Seo SM et al. Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in Staphylococcus aureus. Int J Antimicrob Agents 2003; 22: 254-61.
12. Khan IA, Mirza ZM, Kumar A et al. Piperine, a phytochemical potentiator of ciprofloxacin against Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 810-2.
13. Mullin S, Mani N, Grossman TH. Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitor biricodar (VX-710) and timcodar (VX-853). Antimicrob Agents Chemother 2004; 48: 4171-6.
14. Schmitz F, Fluit A, Luckefahr M et al. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1998; 42: 807-10.
15. Stermitz FR, Lorenz P. Tawara JN et al. Synergy in a Medicinal plant: Antimicrobial action of berberine potentiated by 5-methoxyhynocarpin, a multidrug pump inhibitor. Proc natl Acad Sci USA, 2000; 97: 1433-7.
16. Vidaillac C, Guillon J, Arpin C et al. Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multi-drug efflux pump NorA of Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 831-8.
17. Koul S, Koul JL, Taneja SC et al. Novel 4-alkyl-5-(substituted phenyl)-2 e,4 e-penta dienoic acid amide and its tetrahydro analogues as potentiator of bioeffecacy of anti infectives. US Pre-grant Pub. No. 20070004645, 2006.
18. Kaatz GW, Seo SM, Foster TJ. Introduction of a norA promotor region mutation into the chromosome of fluoroquinolone-susceptible strain of Staphylococcus aureus using plasmid integration. Antimicrob Agents Chemother 1999; 43: 2222-4.
19. Kaatz GW, Seo SM. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 2650-5.
20. Eliopoulus GM. Moellering RCJ. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine, 4th edn. Baltimore, MD: The Williams & Wilkins Co., 1996; 330-96.
21. Drugeon HB, Juvin ME, Bryskier A. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: Comparison with ciprofloxacin, asparfloxacin and ofloxacin. J Antimicrob Chemother 1999; 43 Suppl C: 55-9.
22. Brenwald NP, Gill MJ, Wise R. Prevalence of putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42: 2032-5.
23. Neyfakh AA, Bidnenko VE, Chen LB. Efflux-mediated multidrug resistance in Bacillus subtilis: Similarities and dissimilarities with the mammalian system. Proc Natl Acad Sci USA 1991; 88: 4781-5.
24. Aeschlimann JR, Dresser LD, Kaatz GW et al. Effects of NorA inhibitors on in vitro antibacterial activities and post antibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 335-40.
25. Gibbons S, Oluwatuyi M, Kaatz GW. A novel inhibitor of multi-drug efflux pumps in Staphylococcus aureus. J Antimicrob Chemother 2003; 53 13-7.
26. Ba BB, Arpin C, Vidaillac C et al. Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylocccus aureus strains susceptible to ciprofloxacin or exhibiting various levels and mechanism of ciprofloxacin resistance. Antimicrob Agents Chemother 2006; 50: 1931-6.
27. Piddock LJ, Johnson MM, Simjee S et al. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46: 808-12.
28. Kaatz GW. Bacterial efflux pump inhibition. Curr Opin Investig Drugs 2005; 6: 191-8.
29. Michalet S, Cartier G, David B et al. N-Caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors. Bioorg Med Chem Lett 2007; 17: 1755-8.
30. Vidaillac C, Guillon J, Moreau S et al. Synthesis of new 4-[2-(alkylamino) ethylthio]pyrrolo[1,2-a]quinoxaline and 5-[2-(alkylamino) ethylthio]pyrrolo[1,2-a]thieno[3,2-e]pyrazine derivatives, as potential bacterial multidrug resistance pump inhibitors. J Enzyme Inhib Med Chem 2007; 22: 620-31.
31. Guz NR, Stermitz FR, Johnson JB et al. Flavonolignan and flavone inhibitors of a Staphylococcus aureus multidrug resistance pump: structure-activity relationships. J Med Chem 2001; 44: 261-8.
32. Lomovskaya O, Warran MS, Lee A et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: Novel agents for combination theraphy. Antimicrob Agents Chemother 2001; 45: 105-16.
33. Kern WV, Steinke P, Schumacher A et al. Effect of 1-(1-napthylmethyl)-piperazine, a novel efflux pump inhibitor, on anti-microbial drug susceptibility in clinical isolates of Escherichia coli. J Antimicrob Chemother 2006; 57: 339-43.
34. Stavri M, Piddock LJV, Gibbons S. Bacterial efflux pump inhibitors from natural sources. J Antimicrob Chemother 2007; 59 1247-60.